S100A8 may thus serve as a biomarker for the effectiveness of anti-psoriatic drugs, and combination therapies with solenopsin analogs and other modalities for psoriasis, such as glucocorticoids and UV light, may lead to long-term remission. This evidence concerns the gene S100A8 and psoriasis.